Showing 1 - 2 results of 2 for search 'Matthew Hellmann', query time: 0.01s Refine Results
  1. 1
    Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

    Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status by Mark Awad, Mizuki Nishino, Mehmet Altan, Biagio Ricciuti, Fangxin Hong, Matthew Hellmann, John V Heymach, Joao V Alessi, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

    Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of C... by Chen Zhao, Li Chen, Albrecht Stenzinger, Yali Li, Naiyer Rizvi, Jeff Allen, Matthew Hellmann, Diana M Merino, Lisa M McShane, David Fabrizio, Vincent Funari, Shu-Jen Chen, James R White, Paul Wenz, Jonathan Baden, J Carl Barrett, Ruchi Chaudhary, Wangjuh (Sting) Chen, Jen-Hao Cheng, Dinesh Cyanam, Jennifer S Dickey, Vikas Gupta, Elena Helman, Joerg Maas, Arnaud Papin, Rajesh Patidar, Katie J Quinn, Hongseok Tae, Christine Ward, Mingchao Xie, Ahmet Zehir, Manfred Dietel, Mark Stewart

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: